Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2012

01-10-2012 | Research Article

Cost effectiveness of three drugs for the treatment of S. aureus infections in Nigeria

Authors: Ismail Ayinla Suleiman, Babajide Solomon Bamiro, Fola Tayo

Published in: International Journal of Clinical Pharmacy | Issue 5/2012

Login to get access

Abstract

Background Resistance of microorganisms to existing antimicrobial agents threatens the effective utilization of available resources in sub-Saharan Africa. Cost-effective utilization of antibacterial agents is essential in effective health care delivery in Nigeria. Objectives To determine the most cost effective antibacterial agent in the treatment of S. aureus infections in Lagos metropolis. Setting The study was carried out in a teaching hospital, a specialist hospital, a referral center and two private hospitals. Methods Cost effectiveness analysis of ciprofloxacin, cefuroxime and gentamicin identified to be most effective agent against 463 clinical isolates of S. aureus obtained from the five hospitals was carried out on the basis of societal, health care and third party perspectives using ‘decision table” as an analytical model. Criteria considered in the model included degree of efficacy of the agents, adherence tendencies and tolerability. Both direct (cost of drugs, diagnosis/monitoring, personnel and transportation) and indirect (loss of productivity) costs were evaluated. Main outcome measures These include economic outcome as total therapy cost, clinical outcomes as extent of antibacterial effectiveness obtained from degree of antibacterial efficacy, a proxy measurement of cure rates, and adherence tendency. Humanistic outcome was also measured as tolerability prorated from literature reported degree of adverse drug reactions events, risk of infection and pains from drug administration. Results Ciprofloxacin tablet is a dominant option and much more cost-effective than either cefuroxime or gentamicin in the treatment of S. aureus in Lagos. Regardless of the perspective of analysis, ciprofloxacin has the least cost effectiveness ratio of NGN4214.66 ($28.09), NGN2392.63 ($16.00) and NGN2048.66 ($13.65) from societal, health care and third party payer perspectives, respectively. Sensitivity analysis by increasing the effectiveness index of gentamicin injection-the least cost effective option to the value for the most cost effective option did not change the results. Conclusion Ciprofloxacin should be used as first-line-treatment of S aureus in Lagos as it will lead to significant cost savings in the treatment of S. aureus infections.
Appendix
Available only for authorised users
Literature
1.
go back to reference Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:1.CrossRef Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:1.CrossRef
2.
go back to reference Franco BE, Martínez MA, Rodríguez MAS, Wertheimer AI. The determinants of the antibiotic resistance process. Infect Drug Resist. 2009;2:1–11.PubMed Franco BE, Martínez MA, Rodríguez MAS, Wertheimer AI. The determinants of the antibiotic resistance process. Infect Drug Resist. 2009;2:1–11.PubMed
3.
go back to reference World Health Organisation. Global strategy for containment of anti-microbial resistance. Geneva, Switzerland: World Health Organisation, 2001; WHO/CDS/CSR/DRS/2001.2. World Health Organisation. Global strategy for containment of anti-microbial resistance. Geneva, Switzerland: World Health Organisation, 2001; WHO/CDS/CSR/DRS/2001.2.
4.
go back to reference Adesida S, Bockens, H, Babajide, B, Kehinde, A, Snijders, S, van Leeuwen W. et al. A major epidemic clones of Staphylococcus aureus in Nigeria. Microb Drug Resist. 2005 Summer;11(2):115–121. Adesida S, Bockens, H, Babajide, B, Kehinde, A, Snijders, S, van Leeuwen W. et al. A major epidemic clones of Staphylococcus aureus in Nigeria. Microb Drug Resist. 2005 Summer;11(2):115–121.
5.
go back to reference Suleiman IA, Tayo F. Comparative costs of antibacterial usage in sexully transmitted infections in a Nigerian teaching hospital. Trop J Pharm Res. 2010;9(6):549–55. Suleiman IA, Tayo F. Comparative costs of antibacterial usage in sexully transmitted infections in a Nigerian teaching hospital. Trop J Pharm Res. 2010;9(6):549–55.
7.
go back to reference Webler JT, Courvalin P. An empty quiver: antimicrobial drugs and resistance. Emerg Infect Dis. 2005;11(6):791–3.CrossRef Webler JT, Courvalin P. An empty quiver: antimicrobial drugs and resistance. Emerg Infect Dis. 2005;11(6):791–3.CrossRef
8.
go back to reference Drummond MF. Method for the Economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; Preview 2005. ISBN: 0-19-852945-7. Drummond MF. Method for the Economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; Preview 2005. ISBN: 0-19-852945-7.
10.
go back to reference Murray PR, Baron FJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. ISBN: 1555812554, 9781555812553. Murray PR, Baron FJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. ISBN: 1555812554, 9781555812553.
11.
go back to reference National Committee for Clinical Laboratory Standard Institute (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7 NCCLS, Wayne, PA. The Committee 2001. National Committee for Clinical Laboratory Standard Institute (NCCLS). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7 NCCLS, Wayne, PA. The Committee 2001.
12.
go back to reference Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A10, Wayne, PA: Clinical and Laboratory Standards Institute; 2009. ISBN: 1562385887, 9781562385880. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A10, Wayne, PA: Clinical and Laboratory Standards Institute; 2009. ISBN: 1562385887, 9781562385880.
13.
go back to reference Cano SB, Fujita NK. Formulary evaluation of third generation cephalosporins using decision analysis. Am J of Hosp Pharm. 1988;45:566–9. Cano SB, Fujita NK. Formulary evaluation of third generation cephalosporins using decision analysis. Am J of Hosp Pharm. 1988;45:566–9.
14.
go back to reference Suleiman IA, Tayo F. Pharmacoeconomic evaluation of antimicrobial agents in the treatment of sexually transmitted diseases in Lagos University Teaching Hospital. West Afr J Pharm. 2004;18(1):42–52. Suleiman IA, Tayo F. Pharmacoeconomic evaluation of antimicrobial agents in the treatment of sexually transmitted diseases in Lagos University Teaching Hospital. West Afr J Pharm. 2004;18(1):42–52.
15.
go back to reference Neithimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21:233–41. Neithimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm. 1986;21:233–41.
16.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo; 2011. ISSN: 1726-4898, ISBN: 978-82-8082-477-6. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo; 2011. ISSN: 1726-4898, ISBN: 978-82-8082-477-6.
17.
go back to reference Joel E, Sagel BA. Cost of illness studies—a primer. North Carolina: RTI International RTI-UNC Centre for Excellence in Health promotion Economics; 2006. Joel E, Sagel BA. Cost of illness studies—a primer. North Carolina: RTI International RTI-UNC Centre for Excellence in Health promotion Economics; 2006.
18.
go back to reference Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q. 1982;60(3):429–62.CrossRef Hodgson TA, Meiners MR. Cost of illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q. 1982;60(3):429–62.CrossRef
19.
go back to reference Taylor O, Chukwani CM, Eniojukan JF, Fajemirokun O. Socioeconomic evaluation of parenteral antibacterial therapy in Lagos University Teaching Hospital. Results of a retrospective survey. West Afr J Pharm. 1997;11(2):78–86. Taylor O, Chukwani CM, Eniojukan JF, Fajemirokun O. Socioeconomic evaluation of parenteral antibacterial therapy in Lagos University Teaching Hospital. Results of a retrospective survey. West Afr J Pharm. 1997;11(2):78–86.
20.
go back to reference Mandell LA. Improved safety profile of newer fluoroquinolone. In: Ronald AR, Low DE, editors. Fluoroquinolone Antibiotics. Basel: Birkhauser; 2003. pp. 73–86. ISBN: 3-7643-6591-9. Mandell LA. Improved safety profile of newer fluoroquinolone. In: Ronald AR, Low DE, editors. Fluoroquinolone Antibiotics. Basel: Birkhauser; 2003. pp. 73–86. ISBN: 3-7643-6591-9.
21.
go back to reference American Hospital Formulary Services Drug information® AHFS. 1999 edition. Bethesda, MD, USA: American Society of Health-System Pharmacists. American Society of Health-System Pharmacists Inc.1999; pp. 123–226. ISBN: 978-1-58528-247-0. American Hospital Formulary Services Drug information® AHFS. 1999 edition. Bethesda, MD, USA: American Society of Health-System Pharmacists. American Society of Health-System Pharmacists Inc.1999; pp. 123–226. ISBN: 978-1-58528-247-0.
22.
go back to reference Bank NU, Kammer RB. Heamatologic complications associated with β-lactam antibiotics. Rev Infect Dis. 1983;5:S380–98.CrossRef Bank NU, Kammer RB. Heamatologic complications associated with β-lactam antibiotics. Rev Infect Dis. 1983;5:S380–98.CrossRef
23.
go back to reference Kahlmeter G, Dahlager JI. Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9–22.PubMed Kahlmeter G, Dahlager JI. Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984;13(Suppl A):9–22.PubMed
24.
go back to reference Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, König B, König W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol. 2009;47(9):2975–80. (Epub 2009 Jul 1).PubMedCrossRef Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, König B, König W. Emergence of a community-associated methicillin-resistant Staphylococcus aureus strain with a unique resistance profile in Southwest Nigeria. J Clin Microbiol. 2009;47(9):2975–80. (Epub 2009 Jul 1).PubMedCrossRef
25.
go back to reference Terry Alli OA, Ogbolu DO, Akorede E, Onemu OM, Okanlawon BM. Distribution of mecA gene amongst Staphylococcus aureus isolates from South western Nigeria. Afr J Biomed Res. 2011;14(1):9–16. Terry Alli OA, Ogbolu DO, Akorede E, Onemu OM, Okanlawon BM. Distribution of mecA gene amongst Staphylococcus aureus isolates from South western Nigeria. Afr J Biomed Res. 2011;14(1):9–16.
26.
go back to reference Pablos AI, Escober L, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy programme. Pharmacoepidemiol Drug Saf. 2005;14(1):53–9.PubMedCrossRef Pablos AI, Escober L, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy programme. Pharmacoepidemiol Drug Saf. 2005;14(1):53–9.PubMedCrossRef
27.
go back to reference Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631–9.PubMedCrossRef Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631–9.PubMedCrossRef
Metadata
Title
Cost effectiveness of three drugs for the treatment of S. aureus infections in Nigeria
Authors
Ismail Ayinla Suleiman
Babajide Solomon Bamiro
Fola Tayo
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9671-x

Other articles of this Issue 5/2012

International Journal of Clinical Pharmacy 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine